Skip to main content
. 2018 Sep 19;7(1):211–231. doi: 10.1016/j.jcmgh.2018.09.011

Figure 1.

Figure 1

Alteration of macrophage mTORC1 activity in patients with NASH. (A) H&E sections of mild and severe NASH human liver sections. Scale bar: 100 μm. (B) NAFLD activity scores of human liver samples. (C) Representative immunofluorescence staining of phospho-S6 (p-S6; green) and the macrophage marker CD68 (red) in human liver sections from patients with either mild or severe NASH. Scale bar: 6 μm. (D) Quantification of mean integrated optical density of p-S6 in CD68-positive cells. (E) Representative immunofluorescence staining of total S6 (green) and macrophage marker CD68 (red) in human liver sections reflecting mild or severe NASH. Scale bar: 6 μm. (F) Quantification of mean integrated optical density of S6 in CD68-positive cells. (A–F) n = 5 in each group. (G) Representative immunofluorescence staining of p-S6 (green) and the macrophage marker CD68 (red) in human liver sections from patients with either simple steatosis or mild NASH. Scale bar: 6 μm. (H) Quantification of mean integrated optical density of p-S6 in CD68-positive cells. (G and H) n = 4–5 in each group. Arrows indicate liver macrophage; each point represents an individual human sample; horizontal lines indicate the mean value, and error bars represent the SEM. *P < .05. DAPI, 4′,6-diamidino-2-phenylindole.